glp 1 agonist dementia Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and in Diabetes Mellitus Frontiers | GLP-1 Receptor Agonists:

GLP1 receptor agonists (e.g., semaglutide) and dual GLP1 receptor agonists/GIP agonists (e.g., tirzepatide) have been shown to significantly reduce weight in patients with obesity, with and without type 2 diabetes

Glucagon-like peptide-1: from extract to agent

McGraw-Hill / Lange Rivera FB et al (2024): Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

Longwell, C

Businesses that break the rules will face license cancellation, fines, and legal action

A recent study found that GLP-1 drugs like Ozempic and Wegovy may improve breast cancer survival and recurrence in those with obesity and related health conditions